CoChat

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors

Open access

The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index; 14 of the 34 sources its claims cite were checked for support.

Abstract

BACKGROUND: Plasma chromogranin A (CgA) is related to tumor burden and recommended in the follow-up of patients diagnosed with neuroendocrine tumors (NETs). The use of CgA in the workup of a suspected NET is more questionable. OBJECTIVE: To assess the positive predictive value (PPV) of CgA plasma concentrations above the upper reference limit (URL) in patients with suspected NET. METHOD: Patients referred to the NET Centre, Rigshospitalet, Copenhagen from 2015 to 2019 with clinically suspected NET were included if a CgA measurement was performed prior to referral. The utility of CgA was assessed by comparing pre-referral CgA concentrations to the outcome of a thorough workup. In 47 selected cases with continuously unexplained elevated CgA concentrations, a processing-independent analysis (PIA) for CgA was performed. RESULTS: A total of 197 patients were included. NET was ultimately diagnosed in 25 patients. CgA plasma concentrations were above the URL (elevated) in 19/25 patients diagnosed with NET. In total, 167/197 had elevated CgA concentrations at referral. The positive predictive value (PPV) of elevated CgA concentration was 11% (19/167). Proton pump inhibitor (PPI) treatment was identified as the possible cause of CgA elevation in 55/148 patients with falsely elevated CgA. CgA concentration was normal in 28/47 patients when using PIA. CONCLUSION: Our data do not support using measurement of CgA for screening when NET is suspected since the PPV was rather low. PPI treatment is a common cause of increased CgA concentrations and should always be discontinued before CgA measurement. PIA of CgA could be a way of excluding NET when suspicion is based primarily on elevated CgA.

Overview

CoChat Summary

TL;DR

In 197 patients referred to a specialized NET centre with suspected neuroendocrine tumors, elevated pre-referral plasma chromogranin A (CgA) had a positive predictive value of only 11% for a subsequent NET diagnosis. The authors conclude CgA is unsuitable for screening in suspected NET, that proton pump inhibitor (PPI) treatment is a frequent cause of false elevation, and that processing-independent analysis (PIA) of CgA may help exclude NET when suspicion rests mainly on elevated CgA.

Key findings

  • NET was ultimately diagnosed in 25/197 patients; CgA was elevated in 19/25 (sensitivity 76%) and normal in 6/25 (24%). Sensitivity was 50% for localized disease, 80% with local lymph node metastases, and 100% with distant metastases.
  • Of 167 patients with elevated pre-referral CgA, only 19 had NET, giving a PPV of 11%; this rose to 15% (16/109) when PPI-treated patients were excluded, and to 67% when CgA was severely elevated (>8 × URL) and PPI-treated patients were excluded. PPV in PPI-treated patients was 5%.
  • PPI treatment was identified as a possible cause of CgA elevation in 55/148 patients with falsely elevated CgA; after discontinuing PPI for at least one week, CgA normalized in 28/46 cases, with mean concentration falling from 445 pmol/L (IQR 197–456) to 128 pmol/L (90–152), p < 0.0001.
  • CgA PIA was normal in 28/47 patients with continuously unexplained elevated CgA340-348; in five cases this was used to disprove NET suspicion without further examinations.
  • Risk of NET rose with CgA concentration: OR 1.12 per 100 pmol/L increase (p < 0.005), and 1.18 when PPI-treated patients were excluded (p < 0.001); no significant association was seen in PPI-treated patients (OR 0.96, p = 0.74).

Methods

  • Retrospective single-centre study at the ENETS Centre of Excellence, Rigshospitalet, Copenhagen; patients referred 1 January 2015–31 December 2019 with clinically suspected or histologically verified NET were included if plasma CgA had been measured before referral. Exclusions (n = 32) were CgA measured with another assay, CgA measured after histological NET verification, or incomplete workup, leaving 197 patients (median age 60 years, range 20–88; 67% female).
  • Pre- and post-referral CgA was measured with an in-house CgA340-348 radioimmunoassay (URL 130 pmol/L; inter-assay CV 11%); PIA of CgA (URL 1100 pmol/L) was performed in 47 selected cases with unexplained persistently elevated CgA.
  • PPV, sensitivity, and odds ratios (binary logistic regression per 100 pmol/L CgA) were calculated; PPI discontinuation comparisons used the Wilcoxon signed rank test (SPSS 26).

Limitations

  • Stated by the paper: patients with normal CgA are presumably rarely referred, so the authors likely do not see most true-negative and possibly some false-negative measurements; this could overestimate diagnostic sensitivity and underestimate specificity, and negative predictive value/specificity were therefore not calculated.
  • Stated by the paper: PPI was paused for at least one week, and a longer pause might have normalized CgA in more cases.
  • Evident from the text: the study is retrospective and single-centre, restricted to G1/G2 NETs (G3 NET and NEC patients were referred elsewhere, as were pituitary, thyroid, parathyroid, and adrenal cases), and the PIA subgroup (n = 47) was selected rather than consecutive.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/diagnostics10110881

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Identified processing products of chromogranin A (CgA). The fragments have been suggested to be bioactive with different primarily inhibitory effects. The CgA340-348 sequence does not undergo post-translational processing. CgA340-348 is located between tryptic cleavage sites and one CgA340-348 fragment will be released per CgA molecule when a sample is pre-incubated with trypsin, thus providing an accurate measure of the total CgA concentration of the sample.
Figure 1 Identified processing products of chromogranin A (CgA). The fragments have been suggested to be bioactive with different primarily inhibitory effects. The CgA340-348 sequence does not undergo post-translational processing. CgA340-348 is located between tryptic cleavage sites and one CgA340-348 fragment will be released per CgA molecule when a sample is pre-incubated with trypsin, thus providing an accurate measure of the total CgA concentration of the sample.CC BY · PubMed Central
Figure 2 Flowchart of included and excluded patients, pre-referral CgA plasma concentration levels and total number of neuroendocrine tumors diagnosed.
Figure 2 Flowchart of included and excluded patients, pre-referral CgA plasma concentration levels and total number of neuroendocrine tumors diagnosed.CC BY · PubMed Central
Figure 3 CgA plasma concentrations (pmol/L) in all patients with discontinued proton pump inhibitor (PPI) treatment. Plasma concentrations were measured using the CgA340-348 radioimmunoassay during PPI treatment (pre-referral) and after discontinuation of PPI for at least one week (post-referral).
Figure 3 CgA plasma concentrations (pmol/L) in all patients with discontinued proton pump inhibitor (PPI) treatment. Plasma concentrations were measured using the CgA340-348 radioimmunoassay during PPI treatment (pre-referral) and after discontinuation of PPI for at least one week (post-referral).CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 0 Not valid · 4 Not checked · 44 Own results and interpretations

36 more claims · 1 with their cited sources checked

Create a free account to see all 58 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 6
  • It may state two separate claims as one. 10
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Cited by

See all 17

Metadata

Authors
Baekdal, J., Krogh, J., Klose, M., Holmager, P., Langer, S. W., Oturai, P., Kjaer, A., Federspiel, B., Hilsted, L., Rehfeld, J. F., Knigge, U., & Andreassen, M.
Affiliations
  • ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
  • Copenhagen University Hospital (DK)
  • University of Copenhagen (DK)
Venue
Diagnostics
Publisher
MDPI AG
Published
2020-10-29
Volume
10
Issue
11
Pages
881
ISSN
2075-4418 (ISSN-L)
OpenAlex
W3096514914
Cited by
17
References
44
Citations by year
2026: 3 · 2025: 6 · 2022: 7 · 2021: 1
FWCI
1.43
Type
journal article
Language
en
Open access
Locations
  • Diagnostics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
Keywords
chromogranin A, neuroendocrine tumors, diagnostic accuracy, positive predictive value, proton pump inhibitors, cancer screening, plasma biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.